Clinical Trials Browser

Phase 3 × fluzoparib × Breast × Clear all

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

Fludzoparib" and Anti-angiogenic

NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase 3 Active not recruiting

Breast Cancer Metastatic

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation